Christine Lennon takes us through the latest research and therapeutic implications of PEA and its sister compound: oleoylethanolamide (OEA).
In 1998, the World Health Organization (WHO) estimated there would be 300 million people globally living with type 2 diabetes mellitus (T2DM) by 2025.1 In 2017, the actual figures were
462 million (6.28% of the world’s population) well surpassing the estimations eight years earlier, with a projected increase of 7,079 people diagnosed per 100,000 by 2030. T2DM prevalence is continuing to rise at a rapid rate and continues to be a serious public health consideration.2
The common risk factors for this metabolic condition caused by impaired glucose tolerance leading to insulin resistance include genetic predisposition, age, and lifestyle factors, such as diet and physical activity levels.1,2 In the last decade an increasing amount of research has focussed on the impact of sleep dysregulation as a prominent factor for metabolic health and T2DM development.1
What arre the mechanisms by which protein is influencing weight and appetite control?
For the first time, researchers have shown in an experimental model that commensal bacteria may affect hunger and satiety through their influence on gut-brain signals and activation of appetite-regulated brain neurons.
